Regeneron to Acquire 23andMe for $256 Million, Expanding Genetics-Driven Drug Discovery Capabilities
• Regeneron Pharmaceuticals has won the bankruptcy auction for 23andMe's assets with a $256 million bid, aiming to maintain the consumer genetics service while enhancing its drug discovery platform.
• The acquisition includes 23andMe's Personal Genome Service, Total Health, Research Services, and Biobank assets, but excludes the Lemonaid Health business.
• Regeneron has committed to prioritizing privacy and ethical use of customer data, working with a court-appointed Customer Privacy Ombudsman to ensure compliance with existing policies.
Titan SGSâ„¢ Stapler Shows Significant Reduction in Post-Operative GERD Following Sleeve Gastrectomy
• A new retrospective study published in Obesity Surgery demonstrates that Teleflex's Titan SGS™ Stapler significantly reduces post-operative GERD rates following sleeve gastrectomy compared to traditional multi-fire staplers.
• The study of 257 patients showed only 7.1% of Titan SGS™ patients reported GERD at one-year post-procedure versus 26.4% in the multi-fire cohort, while maintaining equivalent weight loss outcomes.
• Researchers attribute the improved outcomes to the stapler's 23cm single-fire continuous staple line, which creates more consistent and symmetrical sleeve anatomy without kinks that can cause narrowing.
FDA Expands QuikClot Control+ Hemostatic Device Indications to All Bleeding Grades
• Teleflex's QuikClot Control+ Hemostatic Device received FDA 510(k) clearance for expanded use in all grades of internal and external bleeding, significantly broadening its clinical applications beyond severe bleeding scenarios.
• The expanded indication was supported by real-world evidence from a rigorous observational study of 603 emergency, trauma, and surgical patients across multiple U.S. sites, demonstrating safety and efficacy.
• This regulatory milestone is expected to add more than $150 million to Teleflex's serviceable addressable market in the United States, extending the device's use to general, gynecologic, and orthopedic surgeries.
UroLift System Demonstrates Superior Patient Outcomes in Head-to-Head BPH Treatment Trials
• New clinical data presented at the 2025 AUA Annual Meeting shows the UroLift System provides better early patient satisfaction and faster symptom relief compared to Rezūm and tamsulosin for BPH treatment.
• Two randomized controlled trials revealed UroLift patients experienced shorter catheterization times, better sexual function outcomes, and higher overall satisfaction during early recovery periods.
• Real-world data from the American Urological Association Quality Registry confirms UroLift provides rapid symptom improvement at three months, reinforcing its position as a leading minimally invasive BPH treatment option.
© Copyright 2025. All Rights Reserved by MedPath